Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
Close
  • Menu
  • Setting

AP1903

Catalog No.
B4168
FKBP-binding ligand
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$520.00
In stock
5mg
$200.00
In stock
10mg
$320.00
In stock
50mg
$1,000.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

No Related Posts

Background

AP1903 (CAS 195514-63-7) is a synthetic homodimer of an FKBP-binding ligand, engineered to specifically bind and modulate proteins fused to FKBP domains. By inducing controlled dimerization of FKBP fusion proteins, AP1903 functions as a chemical inducer of signal transduction pathways. In fluorescence polarization assays, AP1903 inhibits the mutant F36V-FKBP with an IC50 of 5 nM. In engineered HT1080 human fibrosarcoma cells, AP1903 induces apoptosis via FKBP fusion protein activation, showing an EC50 of approximately 0.1 nM. Its application in vivo has been demonstrated in mouse models engineered for conditional cell ablation, where administration of AP1903 produced a dose-dependent reduction of targeted cell populations (EC50: 0.4 mg/kg). AP1903 is used extensively in biomedical research to study controlled protein activation and apoptosis pathways.

References:
[1] Clackson T, Yang W, Rozamus LW, Hatada M, Amara JF, Rollins CT, Stevenson LF, Magari SR, Wood SA, Courage NL, Lu X, Cerasoli F Jr, Gilman M, Holt DA.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42.
[2] Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, Clackson T, Berger HJ.   Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol. 2001 Aug;41(8):870-9.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt1411.63
Cas No.195514-63-7
FormulaC78H98N4O20
Solubility≥23.53 mg/mL in DMSO; insoluble in H2O; ≥56.2 mg/mL in EtOH
SDFDownload SDF
Canonical SMILESO=C([C@@H](C(C=C1OC)=CC(OC)=C1OC)CC)N2[C@H](C(O[C@@H](C3=CC=CC(OCC(NCCNC(COC4=CC([C@H](CCC(C=C5OC)=CC=C5OC)OC([C@H]6N(C([C@@H](C(C=C7OC)=CC(OC)=C7OC)CC)=O)CCCC6)=O)=CC=C4)=O)=O)=C3)CCC(C=C8)=CC(OC)=C8OC)=O)CCCC2
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Kinase experiment [1]:

FKBP Binding Assay

Subsaturating concentrations of protein were incubated for 30 min with 2.5 nM fluoro-FK506 and serial dilutions of competitor ligand in the wells of a Dynatech microfluor plate. Polarization was read on a Jolley FPM-2 (Jolley Consulting and Research, Grayslake, IL). The increase in polarization on binding was used as a direct readout of percentage of bound probe, compared with controls containing no competitor (100%) or no protein (0%). The concentration of competitor resulting in a 50% probe displacement (IC50) was determined by a nonlinear least square fit by using the four-parameter algorithm.

Cell experiment [1]:

Cell lines

Cloned HT1080 cell lines (ATCC CCL-121)

Preparation method

Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reaction Conditions

37°C

Applications

The human fibrosarcoma line HT1080 was engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human Fas intracellular domain. AP1903 elicits potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50 of ≈0.1 nM.

Animal experiment [1]:

Animal models

Male nu/nu mice

Dosage form

intravenous injection at 0.01-100 mg/kg

Preparation method

Formulated in [50% N,N-dimethylacetamide/50% (90% PEG-400/10% Tween 80)] at 2 ml/kg

Applications

Male nu/nu mice were injected with HT1080 cell line expressing a Fas-F36V-FKBP construct that also constitutively secretes hGH. AP1903 exhibits a dose-dependent decrease in serum hGH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Clackson T, Yang W, Rozamus LW et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42

Quality Control